{"id":48920,"date":"2022-09-28T16:01:50","date_gmt":"2022-09-28T14:01:50","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/global-in-vivo-cro-market-report-2022-increase-in-offshoring-medical-device-manufacturing-to-emerging-countries-driving-growth-researchandmarkets-com\/"},"modified":"2022-09-28T16:01:50","modified_gmt":"2022-09-28T14:01:50","slug":"global-in-vivo-cro-market-report-2022-increase-in-offshoring-medical-device-manufacturing-to-emerging-countries-driving-growth-researchandmarkets-com","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/global-in-vivo-cro-market-report-2022-increase-in-offshoring-medical-device-manufacturing-to-emerging-countries-driving-growth-researchandmarkets-com\/","title":{"rendered":"Global In Vivo CRO Market Report 2022: Increase in Offshoring Medical Device Manufacturing to Emerging Countries Driving Growth – ResearchAndMarkets.com"},"content":{"rendered":"
\n

DUBLIN–(BUSINESS WIRE)–The “Global In Vivo CRO Market Size, Share & Trends Analysis Report by Type (Rodent, Non-Rodent), by GLP Type (Non-GLP, GLP Toxicology), by Indication (Pain Management, Oncology), by Region (North America, APAC), and Segment Forecasts, 2022-2030”<\/a> report has been added to ResearchAndMarkets.com’s<\/strong> offering.\n<\/p>\n

<\/a><\/p>\n

\nThe global in vivo CRO market size is expected to reach USD 7.92 billion by 2030, registering a CAGR of 8.2% It is expected to expand at a CAGR of 8.5% during the forecast period. Increasing focus on core competencies by the pharmaceutical players coupled with economic efficiency offered for outsourcing is expected to boost the demand.\n<\/p>\n

\nIn Addition, the CROs are equipped with a competent workforce capable of performing a diverse number of tasks along with being well-versed through regulatory requirements. Also, the pressure from the increasing competition owing to the rapid growth of generics, patent expirations, and introduction of biosimilar equivalents are encouraging pharmaceutical companies to take the aid of such organizations.\n<\/p>\n

\nIncreasing mergers and collaborations have propelled the value of pharmaceutical outsourcing with major industry contributors expanding into developing regions. The year 2015 experienced high valued transactions as a result of LabCorp acquiring Covance for USD 5.5 billion and the Chinese Private Equity Group acquiring WuXifor for USD 3.3 billion. The patent cliff, high research and development cost involved, and globalization in the clinical trial process has driven the\n<\/p>\n

\nIn Vivo CRO Market Report Highlights<\/strong>\n<\/p>\n